Dr. Michael Draper is currently the Head of Cardiovascular External Innovation at Sanofi. He has more than 15 years of research and development experience in the pharmaceutical industry at both large and small pharmaceutical companies. After completing his postdoctoral studies, he joined the organization that later became Aventis Pharmaceuticals as a Senior Scientist. In 2000, he joined Paratek Pharmaceuticals. During his time at Paratek, he managed discovery, clinical operations, and regulatory affairs and advanced multiple compounds into the clinic. He has been the Principal Investigator for Phase I and II SBIR grants and an Investigator on a Bill and Melinda Gates foundation grant to discover new tetracyclines for filariasis. Dr. Draper has held several adjunct faculty positions throughout his career. He received his M.S. degree from the University of Connecticut and his Ph.D. in Genetics from the University of New Hampshire. He conducted his postdoctoral work at Tufts University with Dr. Stuart Levy. He has his Regulatory Affairs Certification and is an inventor on multiple patents. In his current role at Sanofi he responsible for setting up partnerships with major academic and medical institutions, biotechnology companies, and disease foundations.
Head of Cardiovascular External Innovation